All lobbying filings

STEALTH BIOTHERAPEUTICS INC.

Lobbying for STEALTH BIOTHERAPEUTICS INC. · Developing therapies to treat mitochondrial dysfunction.

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2026 · Massachusetts · House · Senate · $120,000.00 expenses · posted Apr 20, 2026

Official filing document

Bills named in this filing 9

HR 1262
Mikaela Naylon Give Kids a Chance Act
S 932
Give Kids a Chance Act of 2025
HR 1532
Scientific EXPERT Act of 2025
S 822
Scientific EXPERT Act of 2025
HR 4121
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026
S 2256
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026
HR 6280
Access to Genetic Counselor Services Act of 2025
S 3607
Access to Genetic Counselor Services Act of 2026
HR 4709
Newborn Screening Saves Lives Reauthorization Act of 2025

Lobbying activity 1

Health Issues

H.R. 1262/S. 932 - Mikaela Naylon Give Kids a Chance Act General discussions about ultra-rare diseases General discussions about ultra-rare disease drug development General discussions about regulatory reform, including scientific-focused drug development meetings General discussions about mitochondrial diseases H.R. 1532/S. 822, the Scientific EXPERT Act of 2025FDA Rare Disease Innovation Hub Fiscal Year 2026 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act (H.R. 4121 / S. 2256) H.R.6280/S.3607 - Access to Genetic Counselor Services Act of 2025/Access to Genetic Counselor Services Act of 2026 H.R.4709 - Newborn Screening Saves Lives Reauthorization Act of 2025 General discussions about genetic testing, diagnostics General discussions about accelerated approval pathway (AAP)

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.